Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visilizumab for perianal fistulas in Crohn's disease
NCT00267709Phase 2Completed
- Sponsor
- Facet Biotech Corporation
- Start
- Feb 2005
- Primary completion
- Dec 2006
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of visilizumab in Crohn's disease and perianal fistula, sponsored by Facet Biotech Corporation. Primary endpoint: Clinical response. Started Feb 2005; status: completed.
02
Drugs
visilizumab
03
Conditions
Crohn's diseaseperianal fistula
Beyond the preview
Go deeper on NCT00267709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267709.